Clinical Trial: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma

Brief Summary: Consolidation treatment for Primary Central Nervous System Diffuse Large B cell Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX plus Temozolomide,followed by consolidation with Temozolomide in PCNSL patients.

Detailed Summary:
Sponsor: Guangdong General Hospital

Current Primary Outcome: event free survival [ Time Frame: 3 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Chronic neurotoxicity [ Time Frame: 3 year ]
  • Overall survival [ Time Frame: 3 year ]
  • Completed response [ Time Frame: 3 year ]


Original Secondary Outcome: Same as current

Information By: Guangdong General Hospital

Dates:
Date Received: October 13, 2016
Date Started: February 2016
Date Completion: February 2019
Last Updated: October 13, 2016
Last Verified: May 2016